Holen Sie sich die Stockscreener-App
16.62
0.06%
0.01
Handel nachbörslich:
16.75
0.13
+0.78%
Schlusskurs vom Vortag:
$16.61
Offen:
$16.8
24-Stunden-Volumen:
7,026
Relative Volume:
0.28
Marktkapitalisierung:
$88.30M
Einnahmen:
$858.00K
Nettoeinkommen (Verlust:
$-7.82M
KGV:
-11.46
EPS:
-1.4503
Netto-Cashflow:
$-27.59M
1W Leistung:
-3.32%
1M Leistung:
-1.57%
6M Leistung:
+92.70%
1J Leistung:
+267.63%
1-Tages-Spanne:
$16.62
$17.07
1-Wochen-Bereich:
$16.61
$17.14
52-Wochen-Spanne:
$3.6701
$17.57
Rallybio Corp Stock (RLYB) Company Profile
Firmenname
Rallybio Corp
Sektor
Branche
Telefon
203- 859-3820
Adresse
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
16.62 | 88.30M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-10 | Eingeleitet | Wedbush | Outperform |
| 2022-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-08-23 | Eingeleitet | Cowen | Outperform |
| 2021-08-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Rallybio (NASDAQ: RLYB) Announces CFO Jonathan Lieber's Shift to Part-Time Role Starting September 15, 2026 - Kalkine Media
Rallybio's Jonathan Lieber to Shift to Part-Time CFO Role - TradingView
Rallybio Corp (NASDAQ: RLYB) Stock Price, News & Analysis - Kalkine
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
Rallybio Corp (RLYB) Debt 2025 - Stock Titan
Balyasny Asset Management L.P. Exits Rallybio Corp (RLYB) Stake in 13DG Filing - GuruFocus
Rallybio (RLYB) Holds Near $17 Ceiling as Traders Weigh Breakout PotentialWave Extension - vinanet.vn
Rallybio Company Profile & Introduction - Moomoo
Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen - MarketBeat
Rallybio Corporation (RLYB) holders report 3.56% stake in Schedule 13G/A - Stock Titan
Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio - Stock Titan
RLYB Q1 2026 Earnings: Wider-than-Expected Loss Underscores Cost of Advancing Rare-Disease PipelineEBITDA Estimate Trend - vinanet.vn
Rallybio Corporation (NASDAQ:RLYB) Sees Large Drop in Short Interest - MarketBeat
Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A - Stock Titan
RLYB Q1 2026 Earnings: Wider Loss Highlights Acceleration of Clinical-Spend Run-RateGuidance vs Actual - vinanet.vn
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS - MarketBeat
Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC reports 15% Rallybio Corp (RLYB) stake, including 5% fund holding - Stock Titan
Rallybio Corp 2Q 2026: Revenue $0 Net income $43.67M, EPS $7.53— 10-Q Summary - TradingView
Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership - Stock Titan
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs PersistGeographic Revenue Trends - dars.gov.et
RLYB|Rallybio Corp|Price:16.350|Chg%:+0.160 - TradingKey
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Balance Sheet - TradingKey
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest - MarketBeat
RLYB|Rallybio Corp|Price:16.160|Chg%:-0.150 - TradingKey
Rallybio Market Sentiment - Benzinga España
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Rallybio Corporation Revenue Breakdown – FWB:33M0 - TradingView
RLYB Q1 2026 Earnings: Wider-Than-Anticipated Loss as Biotech Continues Clinical InvestmentLong-Term Guidance - vinanet.vn
Rallybio Corporation Revenue Breakdown – TRADEGATE:33M0 - TradingView
Rallybio Corporation (RLYB) Surges 4%: Testing Resistance After Strong Upward MoveIV Contraction - vinanet.vn
Rallybio (RLYB) Gains Momentum After 2.88% Rally, Approaches Key ResistanceImpulse Wave - vinanet.vn
Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics - Stock Titan
Total assets of Rallybio Corporation – FWB:33M0 - TradingView
Price to earnings forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Enterprise value to revenue forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Book value per share of Rallybio Corporation – FWB:33M0 - TradingView
Price to book forward of Rallybio Corporation – FWB:33M0 - TradingView
Long term debt to total equity ratio of Rallybio Corporation – FWB:33M0 - TradingView
Price to sales forward of Rallybio Corporation – FWB:33M0 - TradingView
Enterprise value to EBITDA forward of Rallybio Corporation – FWB:33M0 - TradingView
Net income before discontinued operations of Rallybio Corporation – FWB:33M0 - TradingView
Rallybio Corporation (RLYB) Edges Lower Amid Consolidation Near SupportPercent Below MA - dars.gov.et
Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares - Stock Titan
Rallybio Corporation (RLYB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Finanzdaten der Rallybio Corp-Aktie (RLYB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):